Candidate
Preclinical Precl
Phase 1 Ph1
Phase 2 Ph2
Phase 3 Ph3
Approved Appd
Thyroid Eye Disease
Veligrotug Anti-IGF-1R Thyroid eye disease
Veligrotug Anti-IGF-1R Thyroid eye disease
Approved in the U.S.
Elegrobart Anti-IGF-1R Thyroid eye disease
Elegrobart Anti-IGF-1R Thyroid eye disease
FcRn Inhibitors
VRDN-008 Anti-FcRn Myasthenia gravis
VRDN-008 Anti-FcRn Myasthenia gravis
TSHR Program
VRDN-292 Anti-TSHR Graves’ disease
VRDN-292 Anti-TSHR Graves’ disease